Aspira Women's Health Earnings Call Transcripts
Fiscal Year 2024
-
Q3 2024 saw 4% year-over-year test volume growth and a 2% revenue increase, despite weather disruptions. Secured a $10M ARPA-H grant for EndoInform, gained NY State approval for OvaWatch, and improved gross margin to 60%.
-
Secured $10M ARPA-H funding to accelerate a non-invasive endometriosis diagnostic, targeting commercial launch in two years. OvaWatch and OvaInform advance ovarian cancer diagnostics, while EndoInform leverages multi-omic biomarkers for early detection and chronic management. Combined, these initiatives aim for a $1B+ annual revenue opportunity.
-
Q2 2024 saw record OvaSuite test volumes and a major market expansion with the launch of longitudinal monitoring for OvaWatch. Revenue grew sequentially, margins dipped slightly, and new payer contracts and product development milestones were achieved.